Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nemiralisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 13/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 11/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 9/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 9/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nemiralisib SCHEMBL29493085 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Nemiralisib SCHEMBL29356978 | 1.00 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Nemiralisib SCHEMBL111259 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Nemiralisib SCHEMBL659144 | 0.99 | PIK3CD (0.98) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Nemiralisib SCHEMBL18281137 | 0.98 | PIK3CD (0.97) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL17255824 | 0.94 | PIK3CD (0.88) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Hydrochloric Acid SCHEMBL17255819 | 0.93 | PIK3CD (0.87) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Nemiralisib SCHEMBL18281136 | 0.93 | PIK3CD (0.85) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| Nemiralisib SCHEMBL15051783 | 0.91 | PIK3CD (0.82) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL23140774 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | claimed |
| EP-2632921-B1 | POLYMORPHS AND SALTS OF 6-(1H-INDOL-4-YL)-4-(5-{[4-(1-METHYLETHYL)-1-PIPERAZINYL]METHYL}-1,3-OXAZOL-2-YL)-1H-INDAZOLE AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF E.G. RESPIRATORY DISORDERS | GLAXO GROUP LTD (GB) | 2018-10-17 | — | — | EP | claimed |
| EP-3260453-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2017-12-27 | — | — | EP | claimed |
| EP-2899191-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2017-08-09 | — | — | EP | claimed |
| US-20170015656-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2017-01-19 | — | — | US | claimed |
| US-20160263109-A1 | P13K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-15 | — | — | US | claimed |
| US-20160256466-A1 | PI3K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-08 | — | — | US | claimed |
| EP-3057588-A1 | PI3K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| US-8993576-B2 | 6-(1H-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof | GLAXO GROUP LIMITED (GB) | 2015-03-31 | — | — | US | claimed |
| EP-2424864-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2014-12-03 | — | — | EP | claimed |
| US-8586590-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-19 | — | — | US | claimed |
| US-8580797-B2 | Compounds | Glaxo Smith Kline Intellectual Property Development Limited (GB) | 2013-11-12 | — | — | US | claimed |
| US-20130203772-A1 | Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | claimed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | claimed |
| US-20130131080-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | claimed |
| US-20130096117-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-04-18 | — | — | US | claimed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | claimed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131080-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CB 4/4885PIK3CG 10/4885 |
| US-20170015656-A1 | NOVEL COMPOUNDS | IPO5, IPO4, MAP4 | PIK3CD 2049/4885PIK3CB 1717/4885PIK3CG 1970/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | PIK3CD 73/4885PIK3CB 51/4885PIK3CG 93/4885 |
| US-20130203772-A1 | Polymorphs and Salts | PRKDC, PRKACA, MAP3K6 | PIK3CD 211/4885PIK3CB 279/4885PIK3CG 344/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CB 1706/4885PIK3CG 2718/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CD 2996/4885PIK3CB 3531/4885PIK3CG 3569/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CB 4/4885PIK3CG 10/4885 |
| US-20130096117-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CB 4/4885PIK3CG 10/4885 |
| US-20160256466-A1 | PI3K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | PIK3CA, PIK3R5, PIK3CD | PIK3CD 3/4885PIK3CB 8/4885PIK3CG 4/4885 |
| US-20160263109-A1 | P13K INHIBITOR FOR TREATMENT OF RESPIRATORY DISEASE | PIK3CA, PIK3CD, PIK3R4 | PIK3CD 2/4885PIK3CB 5/4885PIK3CG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.